Abstract：【Objective】To analyze the level of circRNA MICRA in patients with acute myocardial infarction(AMI) and its clinical significance. 【Methods】A total of 73 patients with AMI who were diagnosed in the department of cardiology from January 2017 to May 2018 were enrolled as the AMI group and 73 healthy volunteers examined in the same time period in our hospital were included as healthy controls(HC) group. Venous blood was drawn from subjects immediately at admission to detect level of circRNA MICRA, and AMI patients were followed up 6 months after discharge and the major adverse cardiovascular events(MACE) in the group were recorded. MICRA levels were compared between the AMI and HC groups to explore the difference in level and the correlation between level of MICRA and AMI condition and prognosis. 【Results】Compared to the HC group, the level of MICRA in AMI group was significantly reduced [(1.63±0.28) vs(2.97±0.74), t=14.470, P<0.01];Receiver Operation Characterist Curve(ROC) evaluation of the effectiveness of MICRA as a diagnostic marker for AMI showed that the area under the curve(AUC)(95% CI) was 0.81(0.73-0.90) and the cutoff value was 1.47.Compared to patients with good prognosis, patients with poor prognosis had lower MICRA levels [(0.87±0.22) vs(2.19±0.85), t=12.845, P<0.01]. 【Conclusion】Level of MICRA was down-regulated in AMI patients and was closely related to AMI patient prognosis. It is a potential biomarker for the diagnosis and evaluation of AMI patients.
2021, Vol. 38 
